Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406301 | 0.91 | SLC6A9 (0.54) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116150 | 0.90 | SLC6A9 (0.53) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116170 | 0.89 | SLC6A9 (0.49) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116195 | 0.88 | SLC6A9 (0.51) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116171 | 0.87 | SLC6A9 (0.51) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL10064760 | 0.86 | SLC6A9 (0.51) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116169 | 0.86 | SLC6A9 (0.49) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116183 | 0.86 | SLC6A9 (0.49) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL1000046 | 0.86 | SLC6A9 (0.58) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 | |
| SCHEMBL15116182 | 0.86 | SLC6A9 (0.50) | SLC6A9KCNH2SLC6A5CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | SLC6A9 8/4885KCNH2 1870/4885SLC6A5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.